Effectiveness of Radiofrequency Renal Denervation in the United States: Six-Month Primary End Point Results From the SPYRAL AFFIRM Study
Circulation: Cardiovascular Interventions · 2026-11-03
DOI: 10.1161/circinterventions.126.017422 ↗Abstract
BACKGROUND: Radiofrequency renal denervation (RDN) is a guideline-recommended therapy for uncontrolled hypertension. SPYRAL AFFIRM is a single-arm, postapproval study assessing the efficacy and safety of radiofrequency RDN using the Symplicity Spyral catheter. We report the 6-month primary end point results in the SPYRAL AFFIRM US population. METHODS: Enrolled patients had an office systolic/diastolic blood pressure (BP) ≥140/90 mm Hg and a home systolic BP ≥135 mm Hg. Patients with type 1 diabetes, poorly controlled type 2 diabetes (HbA1c >8.0%), or an estimated glomerular filtration rate
EUVIMED